Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Farmers Insurance
Fuji
McKinsey
Julphar
Healthtrust
QuintilesIMS
Federal Trade Commission
Deloitte

Generated: April 25, 2018

DrugPatentWatch Database Preview

Bristol Company Profile

« Back to Dashboard

Summary for Bristol
International Patents:654
US Patents:23
Tradenames:87
Ingredients:74
NDAs:110
Drug Master File Entries: 1

Drugs and US Patents for Bristol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb ELIQUIS apixaban TABLET;ORAL 202155-002 Dec 28, 2012 RX Yes Yes 9,326,945 ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb PRAVACHOL pravastatin sodium TABLET;ORAL 019898-002 Oct 31, 1991 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 AB RX Yes No 7,125,875 ➤ Try a Free Trial ➤ Try a Free Trial
Bristol BETAPEN-VK penicillin v potassium TABLET;ORAL 061150-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Bristol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb VIDEX didanosine TABLET, CHEWABLE;ORAL 020154-006 Oct 28, 1999 4,861,759*PED ➤ Try a Free Trial
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET, TABLET, TABLET;ORAL 021387-005 Jun 24, 2003 4,346,227*PED ➤ Try a Free Trial
Bristol Myers Squibb VIDEX didanosine FOR SOLUTION;ORAL 020155-005 Oct 9, 1991 4,861,759*PED ➤ Try a Free Trial
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-003 Sep 17, 1998 5,519,021*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BRISTOL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01
➤ Subscribe Tablets 30 mg ➤ Subscribe 2005-06-01
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2010-03-19
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-06-14
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-16
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 2016-07-15
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-11-03
➤ Subscribe Tablets 600 mg ➤ Subscribe 2009-04-09
➤ Subscribe Capsules 300 mg ➤ Subscribe 2009-07-20
➤ Subscribe Capsules 200 mg ➤ Subscribe 2010-02-16
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 2010-06-28
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-17
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2016-12-28

Non-Orange Book US Patents for Bristol

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,486,942 Modulators of pharmacokinetic properties of therapeutics ➤ Try a Free Trial
9,382,219 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
8,716,323 Cyclic protein tyrosine kinase inhibitors ➤ Try a Free Trial
6,858,616 Nitrogen containing heterobicycles as factor Xa inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Bristol Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
01C/001 Belgium ➤ Try a Free Trial PRODUCT NAME: EFAVIRENZ; NATL. REGISTRATION NO/DATE: EU/1/99/110/001 19990604; FIRST REGISTRATION: CH 54908 01 19981120
2014026,C1506211 Lithuania ➤ Try a Free Trial PRODUCT NAME: DAPAGLIFLOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
/2005 Austria ➤ Try a Free Trial PRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005
1304992/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
US Department of Justice
McKesson
AstraZeneca
Accenture
Julphar
Cantor Fitzgerald
Boehringer Ingelheim
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.